Articles

ZIDOVUDINE THERAPY, CD4+ AND CD8+ COUNTS ARE ASSOCIATED WITH A LONGER SURVIVAL FOLLOWING AIDS ONSET

Authors
  • M Fiala
  • J Swartz
  • S Teklehaimanot
  • V Kermani
  • AS Funnye
  • JW Sayre
  • JA Gornbein

Abstract

In 60 patients followed from the onset of acquired immunodeficiency syndrome (AIDS) to death, survival was determined by Cox Proportional Hazards Analysis in relationship to seven variables: time-dependent CD4+ and CD8+ peripheral lymphocyte counts, zidovudine treatment, cytomegalovirus (CMV) retinitis, time from AIDS onset, calendar year of AIDS onset(cohort effect), and age. Two significant prognostic variables were identified: zidovudine therapy and either CD4+ or CD8+ counts (the latter could not be distinguished due to concomitant high correlation). Treatment with zidovudine reduced the death rate by 75% compared to no treatment. When included in a proportional hazards regression with all covariates except for the other T lymphocyte count, every increase in CD4+ count of 10 cells was equivalent to a decline in the mortality rate by 13% (p=0.046), and every increase in CD8+ count of 10 cells lowered the mortality by 1.4% (p=0.0031). Patients treated with zidovudine and without CMV retinitis showed the slowest decline of both CD4+ and CD8+ counts. Both CD4+ and CD8+ levels are useful predictors of survival in patients with AIDS.

How to Cite:

Fiala, M. & Swartz, J. & Teklehaimanot, S. & Kermani, V. & Funnye, A. & Sayre, J. & Gornbein, J., (1997) “ZIDOVUDINE THERAPY, CD4+ AND CD8+ COUNTS ARE ASSOCIATED WITH A LONGER SURVIVAL FOLLOWING AIDS ONSET”, Lymphology 30(3), 128-136.

Downloads:
Download PDF

19 Views

10 Downloads

Published on
28 Aug 1997
Peer Reviewed